The Technical Analyst
Select Language :
Paratek Pharmaceuticals [PRTK]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Paratek Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Paratek Pharmaceuticals is listed at the  Exchange

1.83% $2.23

America/New_York / 20 sep 2023 @ 16:00


Paratek Pharmaceuticals: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 127.83 mill
EPS: -1.110
P/E: -2.01
Earnings Date: Oct 31, 2023
SharesOutstanding: 57.32 mill
Avg Daily Volume: 0.600 mill
RATING 2023-09-29
B-
Neutral
RATINGS
Rating CashFlow: Buy
Return On Equity: Strong Buy
Return On Asset: Sell
DE: Strong Sell
P/E: Sell
Price To Book: Strong Sell
QUARTER GROWTHS
1/222/223/224/221/232/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -2.01 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.34x
Company: PE -2.01 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 2.21 - 2.26

( +/- 1.12%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2023-09-21 Baylor-henry Minnie Sell 32 800 Common Stock
2023-09-21 Baylor-henry Minnie Sell 26 400 Common Stock
2023-09-21 Baylor-henry Minnie Sell 12 800 Stock option (right to buy)
2023-09-21 Hoffmann Rolf K Sell 64 000 Common Stock
2023-09-21 Hoffmann Rolf K Sell 20 000 Common Stock
INSIDER POWER
-63.68
Last 96 transactions
Buy: 1 606 755 | Sell: 5 363 965

Forecast: 01:40 - $2.31

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.23 (1.83% )
Volume 4.48 mill
Avg. Vol. 0.600 mill
% of Avg. Vol 746.42 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Paratek Pharmaceuticals Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Paratek Pharmaceuticals Inc

RSI

Intraday RSI14 chart for Paratek Pharmaceuticals Inc

Last 10 Buy & Sell Signals For PRTK

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Paratek Pharmaceuticals Inc

PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Last 10 Buy Signals

Date Signal @
USDDUSDMar 29 - 06:480.997
ETHWUSDMar 29 - 06:484.35
GRTUSDMar 29 - 06:45$0.398
KCSUSDMar 29 - 06:44$11.84
GTUSDMar 29 - 06:43$9.65
WNXMUSDMar 29 - 06:3872.57
ALPHUSDMar 29 - 06:362.72
LEASHUSDMar 29 - 06:34572.59
FLIPUSDMar 29 - 06:345.05
XMONUSDMar 29 - 06:29911.39

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.